Ireland - English - HPRA (Health Products Regulatory Authority)

intrapharm laboratories limited - dihydrotachysterol - oral drops solution - 250 microgram/ml - dihydrotachysterol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

esteve pharmaceuticals ltd - dihydrotachysterol - oral solution - 250microgram/1ml

Canada - English - Health Canada

sanofi-synthelabo canada inc - dihydrotachysterol - capsule - .125mg - dihydrotachysterol .125mg - vitamin d

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - dihydrotachysterol - tablets - 0.2 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - colecalciferol 1.25mg equivalent to 50,000 iu (plus 12% (0.15 mg) overage) - coated tablet - 1.25 mg - active: colecalciferol 1.25mg equivalent to 50,000 iu (plus 12% (0.15 mg) overage) excipient: acacia   ammonia solution calcium carbonate   castor oil ether gelatin hydrated silica lactose monohydrate magnesium stearate maize starch     methylated spirits povidone powdered cellulose prepared theobroma purified talc     purified water shellac sucrose   titanium dioxide white beeswax - indicated for treatment of vitamin d deficiency associated with malabsorption in children and/or adult patients. indicated for prevention and treatment of vitamin d deficiency states.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.15 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.15 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.